BioSpace News Archive

FDA

Pfizer Bispecific Drug Wins FDA Accelerated Approval for Multiple Myeloma

On the heels of J&J’s Talvey, Pfizer’s bispecific antibody Elrexfio has secured an accelerated approval as another off-the-shelf treatment option for patients with relapsed or refractory multiple myeloma.

August 15, 2023
·
2 min read
·
Tristan Manalac
Deals

Harmony Makes Rare Disease Play with Potential $200M Zynerba Buyout

Following its Scorpion Capital controversy in March, Harmony Biosciences is seeking to deepen its pipeline with an acquisition of Zynerba Pharmaceuticals’ cannabinoid therapies for neuropsychiatric disorders.

August 15, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Galecto Drops Idiopathic Pulmonary Fibrosis Hopeful After Phase II Flop

The company is ending its investigational drug GB0139’s run in idiopathic pulmonary fibrosis after the small-molecule inhibitor failed to slow lung function decline in a Phase IIb study.

August 15, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Design Therapeutics Stock Plunges Amid Redesign of Only Clinical Asset

Following injection site reactions in a Phase I study, the company is developing a new formulation for its Friedreich’s ataxia candidate setting the asset’s clinical progress back significantly.

August 15, 2023
·
2 min read
·
Kate Goodwin
How to Start an Employee Resource Group at Work

Employee resource groups can benefit employee engagement, retention, recruitment and business objectives, according to a new report from BioSpace.

August 15, 2023
·
4 min read
·
Chantal Dresner
Biotech Bay

Incubators Offer Staffing Support for Startups

Biotech startups often struggle with hiring decisions. Incubators can help through mentorship opportunities and by bringing in potential talent.

August 15, 2023
·
4 min read
·
Charlotte LoBuono
Business

Basilea reports strong revenue and profit growth in first half-year 2023

Basilea Pharmaceutica Ltd, Allschwil, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial or fungal infections, announced its financial results for the first half-year ended June 30, 2023.

August 15, 2023
·
8 min read
Drug Development

Spexis announces USD $2.5 million capital commitment to support the upcoming Phase 3 ColiFin® studies

Spexis AG announced a capital commitment totaling USD $2.5 million with participation from SPRIM Global Investments and institutional investors to fund the upcoming Phase 3 ColiFin® studies, beginning with the COPILOT study which is expected to initiate in the third quarter of 2023.

August 15, 2023
·
2 min read
Business

Wheeler Bio Appoints Marc Helouin as Chief Quality and Regulatory Officer

Wheeler Bio, Inc. today announced the appointment of Marc Helouin as Chief Quality and Regulatory Officer (CQRO).

August 15, 2023
·
3 min read
Biotech Bay

Mainz Biomed Announces Financial Half Year Results 2023 and Provides Corporate Update

Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced the results of the first six months and second quarter ending June 30, 2023 and provided a corporate update.

August 15, 2023
·
14 min read